Biltmore Family Office’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $615K | Sell |
10,147
-1,210
| -11% | -$70.5K | 0.09% | 142 |
|
|
2025
Q4 | $613K | Buy |
11,357
+1,160
| +11% | +$55.8K | 0.08% | 136 |
|
|
2025
Q3 | $460K | Buy |
10,197
+5
| +0% | +$234 | 0.07% | 147 |
|
|
2025
Q2 | $472K | Hold |
10,192
| – | – | 0.08% | 130 |
|
|
2025
Q1 | $622K | Hold |
10,192
| – | – | 0.11% | 118 |
|
|
2024
Q4 | $576K | Sell |
10,192
-100
| -1% | -$5.59K | 0.1% | 116 |
|
|
2024
Q3 | $533K | Buy |
10,292
+150
| +1% | +$7.04K | 0.09% | 125 |
|
|
2024
Q2 | $421K | Sell |
10,142
-1,000
| -9% | -$44.7K | 0.08% | 127 |
|
|
2024
Q1 | $604K | Hold |
11,142
| – | – | 0.12% | 99 |
|
|
2023
Q4 | $572K | Sell |
11,142
-1,166
| -9% | -$61.2K | 0.12% | 101 |
|
|
2023
Q3 | $714K | Sell |
12,308
-35
| -0.3% | -$2.15K | 0.16% | 87 |
|
|
2023
Q2 | $789K | Sell |
12,343
-748
| -6% | -$50.2K | 0.17% | 81 |
|
|
2023
Q1 | $907K | Buy |
13,091
+1,012
| +8% | +$71.4K | 0.19% | 78 |
|
|
2022
Q4 | $869K | Buy |
12,079
+1,347
| +13% | +$102K | 0.18% | 79 |
|
|
2022
Q3 | $763K | Sell |
10,732
-111
| -1% | -$8.05K | 0.17% | 75 |
|
|
2022
Q2 | $841K | Sell |
10,843
-777
| -7% | -$59.2K | 0.21% | 74 |
|
|
2022
Q1 | $855K | Sell |
11,620
-1,000
| -8% | -$67.1K | 0.18% | 82 |
|
|
2021
Q4 | $787K | Buy |
12,620
+2,000
| +19% | +$117K | 0.15% | 96 |
|
|
2021
Q3 | $634K | Hold |
10,620
| – | – | 0.15% | 90 |
|
|
2021
Q2 | $710K | Sell |
10,620
-287
| -3% | -$18.7K | 0.2% | 82 |
|
|
2021
Q1 | $694K | Sell |
10,907
-565
| -5% | -$35.2K | 0.22% | 71 |
|
|
2020
Q4 | $717K | Buy |
11,472
+2,064
| +22% | +$127K | 0.22% | 68 |
|
|
2020
Q3 | $567K | Hold |
9,408
| – | – | 0.32% | 69 |
|
|
2020
Q2 | $553K | Hold |
9,408
| – | – | 0.33% | 74 |
|
|
2020
Q1 | $524K | Buy |
9,408
+643
| +7% | +$39.3K | 0.34% | 78 |
|
|
2019
Q4 | $563K | Sell |
8,765
-23,600
| -73% | -$1.35M | 0.23% | 88 |
|
|
2019
Q3 | $1.64M | Buy |
32,365
+23,327
| +258% | +$1.1M | 0.71% | 45 |
|
|
2019
Q2 | $410K | Sell |
9,038
-34,250
| -79% | -$1.6M | 0.22% | 91 |
|
|
2019
Q1 | $2.06M | Sell |
43,288
-50
| -0.1% | -$2.49K | 1.05% | 31 |
|
|
2018
Q4 | $2.25M | Buy |
43,338
+123
| +0.3% | +$6.61K | 1.27% | 26 |
|
|
2018
Q3 | $2.68M | Hold |
43,215
| – | – | 1.28% | 27 |
|
|
2018
Q2 | $2.39M | Sell |
43,215
-195
| -0.4% | -$10.5K | 1.19% | 27 |
|
|
2018
Q1 | $2.75M | Hold |
43,410
| – | – | 1.22% | 26 |
|
|
2017
Q4 | $2.66M | Buy |
+43,410
| New | +$2.72M | 1.2% | 28 |
|
Other funds holding BMY
VCM
VPM
Biltmore Family Office's BMY Position: Q1 2026 in Review
Biltmore Family Office reduced its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2026, selling an estimated $70.5K and leaving 10,147 shares worth $615K. The position accounts for 0.09% of the portfolio, ranked #142.
Biltmore Family Office first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.75M in Q1 2018. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Biltmore Family Office held 10,147 shares of Bristol-Myers Squibb worth $615K as of Q1 2026.
- Biltmore Family Office sold 1,210 Bristol-Myers Squibb shares in Q1 2026, an estimated $70.5K.
- Bristol-Myers Squibb made up 0.09% of Biltmore Family Office's portfolio in Q1 2026, its #142 holding.
- Biltmore Family Office first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- Biltmore Family Office's Bristol-Myers Squibb position peaked at $2.75M in Q1 2018.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Biltmore Family Office's 13F filing for Q1 2026, filed 11 May 2026.